SCHEMBL1335591

SCHEMBL1335591

O=C(F)CCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25200418 0.72
SCHEMBL1190048 0.70
SCHEMBL22731251 0.68
Ethyl Chloride SCHEMBL1052272 0.67 FFAR3 (0.44)
SCHEMBL8532418 0.67
SCHEMBL2672587 0.67
SCHEMBL28290466 0.67
SCHEMBL2671479 0.67
SCHEMBL92092 0.67
SCHEMBL298779 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119118940-A Preparation method of 2-chloromethyl-oxazole 湖南唯美胜科技有限公司 2024-12-13 CN claimed
EP-1436286-B1 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF EQUISPHARM CO LTD (KR) 2009-08-19 EP claimed
US-7087768-B2 6-O-(4-methoxyaniline)acetyl fumagillol for example; superior angiogenesis inhibitory effect with less toxicity, also a cancer metastasis inhibitor, and treats angiogenesis related disorders such as other various inflammatory diseases such as rheumatic disease, psoriasis, and diabetic retinopathy EQUISPHARM CO., LTD. (KR) 2006-08-08 US claimed
EP-1436286-A4 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF IDRTECH INC (KR) 2004-12-15 EP claimed
US-20040242681-A1 Fumagillol derivatives and preparing method thereof EQUISPHARM CO., LTD. (KR) 2004-12-02 US claimed
EP-1436286-A1 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF Idrtech Inc. (KR) 2004-07-14 EP claimed
WO-2003027104-A1 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF IDRTECH INC. (KR) 2003-04-03 WO claimed
US-12605451-B2 Targeted plasma protein degradation NOVARTIS AG (CH) 2026-04-21 US disclosed
US-12209144-B2 Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders NOVARTIS AG (CH) 2025-01-28 US disclosed
CN-119118940-A Preparation method of 2-chloromethyl-oxazole 湖南唯美胜科技有限公司 2024-12-13 CN disclosed
CN-118434793-A Main chain polymer, optical film, method for producing same, and multilayer film 东曹株式会社 2024-08-02 CN disclosed
US-20230398224-A1 TARGETED PLASMA PROTEIN DEGRADATION NOVARTIS AG (CH) 2023-12-14 US disclosed
EP-4100064-A1 TARGETED PLASMA PROTEIN DEGRADATION Novartis AG (CH) 2022-12-14 EP disclosed
WO-2003027104-A1 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF IDRTECH INC. (KR) 2003-04-03 WO disclosed
US-6331653-B1 Process for producing 3,4-dihydroxy-3-cyclobutene-1,2-dione KYOWA YUKA CO., LTD. (JP) 2001-12-18 US disclosed
CN-1269778-A Preparation method of 3, 4-dihydroxy-3-cyclobutene-1, 2-diketone KYOWA YUKA KK (JP) 2000-10-11 CN disclosed
EP-1010684-A1 PROCESS FOR PRODUCING 3,4-DIHYDROXY-3-CYCLOBUTENE-1,2-DIONE Kyowa Yuka Co., Ltd. (JP) 2000-06-21 EP disclosed
CN-1121064-A Process for preparing trifluoroacetyl fluoride HOECHST AG (DE) 1996-04-24 CN disclosed
US-4235815-A N-fluoromethyl-carbamic acid fluorides and their manufacture BASF AKTIENGESELLSCHAFT (DE) 1980-11-25 US disclosed
US-4179465-A N-fluoromethyl-carbamic acid fluorides and their manufacture BASF AKTIENGESELLSCHAFT (DE) 1979-12-18 US disclosed